Useful External Websites
Confronting Pancreatic Cancer Provides information about pancreatic cancer, including treatment, clinical trials and news stories. Pancreatic Cancer Action Network A pancreatic cancer advocacy group....

Adjuvant Chemoradiation Therapy after Surgical Resection for 1092 Cases of Pancreatic Adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic Collaborative Study of Pancreatic Cancer
Presenter: C. C. HsuPresenter's Affiliation: Johns Hopkins Hospital, Baltimore, MDType of Session: ScientificBackground Despite aggressive multimodality treatment, pancreatic cancer is associated with a high rate of mortality. Even the 15-20% of patients who present with resectable disease experience 5-year survivals of only 10-25%.

Feasibility and First Clinical Results of Hypofractionated Scanning Proton-Beam Therapy for Inoperable Pancreatic Cancer
Presenting Author: A. Haidenberger MD Presenting Author Affiliation: Rinecker Proton Therapy Center, Munich Background Pancreatic cancer is an aggressive malignancy, with median survival of 5-8 months after diagnosis. The standard of care is surgical resection and adjuvant chemotherapy or chemoradiation, where feasible, achieving a 5 year

A phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative oncology Group (ECOG) trial
Presenter: J. Berlin Affiliation: ECOG, USA Background: The vast majority of patients with pancreatic cancer are diagnosed with locally advanced unrespectable or advanced disease for which there is no curative therapy. Many chemotherapeutic agents have been evaluated in patients with pancreatic cancer. Gemcitabine (gem) and 5-FU are the